Treatment of Ovarian Cancer

About

Summary: Rutgers and UMDNJ scientists have developed an ovarian tumor-targeted therapeutic delivery system that utilizes anticancer agents, siRNA sequences - an agent for tumor-targeted delivery, and a nanocarrier delivery vehicle such as a liposome or dendrimer. This "multi-prong" attack strategy using both genetic and chemotherapies was constructed to reduce or prevent drug resistance, growth of metastases, and adverse side effects of chemotherapy, which are the major causes of treatment failure in ovarian cancer.  The tumor-targeted delivery system was tested in a mouse xenograft model of human ovarian cancer with intraperitoneal metastases and ascites, using tumors from patients with ovarian cancer. The treatment not only led to the substantial regression of the growth of primary tumor, but also prevented the development of intraperitoneal metastases and limited adverse side effects of chemotherapy on healthy tissues.    Market Application: Therapeutics; Oncology; Cancer; Drug Delivery; Genetic Therapy; Chemotherapy; Ovarian Cancer; TumorTargeting; Nanoparticles; Nanocarriers; siRNA; Cellular Internalization, Veterinary.   Advantages: Delivery system incorporates geno and chemotherapy; reduces chemotherapeutic side effects; addresses growth of both primary tumor and metastases; multiple potential drug delivery platforms.